This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Dialysis  • Alert me on articles by topic

Mike Mitka

JAMA. 2002;287:2643-2644.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—A recently concluded study has failed to show differences in treatment options that would reduce US mortality rates for patients who receive hemodialysis.

The results from the Hemodialysis (HEMO) Study showed that mortality rates were basically the same for patients regardless of combinations of standard or high doses of hemodialysis and low and high dialysis membrane flux. The study results were presented at the National Kidney Foundation's (NKF) Clinical Nephrology Meetings by lead investigator Garabed Eknoyan, MD, a professor of medicine at Baylor College of Medicine in Houston.

Eknoyan said the results were surprising because evidence from observational studies suggested that a higher dose of dialysis resulted in improved patient health.

"The trend had been to give more and more dialysis, with the notion that more is better," Eknoyan said. "But this was based on observational studies. That's why you have to do clinical trials."

AN ELUSIVE . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The impact on resources of increased adequacy targets in haemodialysis
Stratton et al.
Nephrol Dial Transplant 2002;17:2277-2278.
FULL TEXT